

MONTE CARLO APPLICATIONS @ MEDAUSTRON

The use of Monte Carlo Computation Tools in the Hadron Therapy Facility MedAustron

Lukas Jägerhofer, Claudia Lenauer, Marta Mumot, Michael Deutsch, Ivan Strasik, Mauro Pivi,
Andreas F. Resch, Yihan Jia

Photos / Graphics: MedAustron, Thomas Kästenbauer, Freepik/MedAustron, Kästenbauer/Ettl

TABLE OF CONTENTS



- Introduction and status of MedAustron
- FLUKA in Radiation Protection Services
- FLUKA in Accelerator and Beam Physics
- GEANT4 in Medical Physics (Beam Delivery and Monte Carlo)

FACILITY OVERVIEW

Clinical Irradiation Rooms

Three rooms for patient treatments


Research

Irradiation room for non-clinical use

Ion Sources

and linear accelerator

Synchrotron




INTERNATIONALITY



TEAM

~300 employees from
20 different countries



CLINIC


Patients from all over
Austria and abroad




COOPERATIONS

With institutes,
companies,
professional societies
worldwide

COMPANY HISTORY TO FIRST PATIENT




MILESTONES SINCE FIRST PATIENT




RADIOTHERAPY IN GENERAL

- The aim is to **prevent further proliferation** of the tumor cells
- This requires a **high radiation dose** in the tumor cells
- **Organs at risk** tolerate only a low radiation dose




THE PRINCIPLE OF PARTICLE THERAPY



TREATMENT PLANNING - COMPARISON

PHOTONS


IMRT, VMAT, SBRT



Several fields, entry and exit dose

PROTONS


IMPT






Fewer fields, reduced entry dose, no exit dose

DOSE DIFFERENTIAL

Photons minus Protons



PARTICLE TYPES AT MEDAUSTRON




Update in the
upcoming
presentation
by C. Lenauer

Sparing of organs at risk and healthy tissue

Higher dose in the tumor /
application in
radioresistant tumors

INDICATIONS TREATED AT MEDAUSTRON




CNS	25%
Head & Neck	20%
Re-Irradiation	16%
Pediatrics	16%
Sarcoma	12%
Skull Base	5%
Prostate	3%
Gastrointestinal (upper)	2%
Thorax	1%
Gastrointestinal (lower)	<1%
Urogenital Tumors	<1%
Breast/Mamma-Ca	<1%
Gynecological Tumors	<1%

Values (rounded) as of April 2024

Radiation Protection Project

INITIAL AUTHORITY APPROVAL FOR THE FACILITY


SHIELDING CONCEPT IS PART OF AN ENVIRONMENTAL IMPACT ASSESSMENT



Radiation Protection Project


AUTHORITY APPROVAL FOR AN ADDITIONAL IRRADIATION ROOM

A COMMERCIAL SYNCHRO CYCLOTRON FOR PROTON THERAPY




Authority approval expected summer 2024.

Start of construction pending.



0.1 mSv/a 0.6 mSv/a 2.0 mSv/a




mSv/a

1.0e-6 2.7e-5 7.2e-4 1.9e-3 3.7e-3 7.2e-2 1.9e-2 3.7e-2 7.2e-1 1.9e-1 3.7e-1 7.2e+0 1.9e+1 3.7e+1 7.2e+2 1.9e+3 3.7e+3 7.2e+4 1.9e+5 3.7e+5 7.2e+6 1.9e+7 3.7e+7 7.2e+8 1.9e+9

Radiation Protection Project

EXTENSION OF APPROVED ION SPECIES *EFFECTS ON THE SHIELDING*




Nr of primary particles of ion species A


$$D_{ges} = \sum_{A=1}^{A_{max}} N_A \cdot D_A$$

of ion species A

Room with heavy concrete




Room with normal concrete



Radiation Protection Project


MEASUREMENTS AND SIMULATIONS IN IR DURING PATIENT TREATMENT

CAN FLUKA BE USED TO ASSESS DOSE TO PERSON IN THE ROOM IN CASE OF THIS INCIDENT?



Reasonable agreement
btw measurements
and simulations

-> Method might be
valid to assess
personal dose







Radiation Protection Project

ACTIVATION OF WATER

ARE CARBON IONS MORE DANGEROUS THAN PROTONS?


(Bq/g)	After protons		
Nuclide	Activity	σ	MDA
Be-7	0.07	0.01	0.0066
C-11*	2.42	0.31	0.0138
N-13*	8.14	1.04	0.0465

After carbon		
Activity	σ	MDA
0.04	0.03	0.0099
1.75	0.22	0.0102
4.27	0.55	0.0248



Typical treatment plans:


- Less Particles
- Less Activation of phantoms (or immobilization equipment, etc.)




Radiation Protection Project

OPTIMIZATIONS FOR SINUS IRRADIATION


IS A TITANIUM LAYER IN THE BITE SPLINT USEFUL TO REDUCE DOSE EQUIVALENT TO THE PATIENT?




Bite splint made of plastic creates distance to target area -
Titanium inlay increases dose equivalent both during irradiation and afterwards through activation



Dose Equivalent in beam direction



Energy dose in beam direction




Radiation Protection Project


COMMISSIONING OF THE PROTON BEAM MODEL IN FLUKA

FOR ADDITIONAL EVALUATION OF SPECIAL TREATMENT SITUATIONS (E.G. IMPLANTS)

Differences in range (R80) between measurements and FLUKA for proton beams of different energies (current beam model)





Spot size at isocenter - Measurements versus TPS baseline and FLUKA



Radiation Protection Project

EVALUATION OF PROFILES IN AIR – 5X5 SPOTS PLAN



BEST RESULT IF VACUUM WINDOW IS NOT IMPLEMENTED



Radiation Protection Project

EVALUATION OF PROFILES IN AIR – 5X5 SPOTS PLAN

SHOWN FOR 252,7 MEV PROTON BEAM



For ISD58, ISD30 and ISD0 (at isocenter)
FWHMs in agreement
(inside 0.6 mm difference from measurements)

Radiation Protection Project


APPLICATION OF BEAM MODEL IN A TREATMENT PLAN

LEFT WITHOUT BEAM MODEL IMPLEMENTED, RIGHT WITH OPTIMIZED BEAM MODEL FOR PROTONS

Without beam model




With beam model



Radiation Protection Project

APPLICATION OF LEFT WITHOUT BEAM MODEL

Without beam model




Good agreement between FLUKA and commercial TPS for proton beams.

Beam model still needs optimization concerning effective energy in iso center.

Next step Carbon ions!

MENT PLAN WITH BEAM MODEL FOR PROTONS


With beam model



Accelerator and Beam Physics Project

FLUKA SIMULATION OF BEAM SCATTERING IN THE NOZZLE

- MAD-X/PTC particle tracking in the accelerator beam line → recorded particle coordinates.
- Output of MAD-X/PTC at the vacuum window → FLUKA input via the SOURCE sub-routine.
- Beam delivery monitors consist of thin metal and plastic foils with gaps filled by gasses.
- Detailed nozzle model was built using Flair to simulate the beam scattering using FLUKA.
- MULSOPT card included → MCS optimization & single scattering activated.
- Below → FLUKA simulation of the 136.8 MeV proton beam passing through the nozzle.






Courtesy of Ivan Strasik & Mauro Pivi

Accelerator and Beam Physics Project

COLLIMATOR DESIGN USING FLUKA

- FLUKA was used to design a protective collimator in the gantry irradiation room.
- The collimator shall protect the patients in case of a failure of the last dipole magnet -> IEC 60601-2-64 clause 201.10.2.101.4.6. – non primary radiation under fault condiditon
- FLUKA simulations were used to determine the collimator parameters (dimensions, material,).
- Secondary particles generated by the beam which accidentally hits the collimator, are also evaluated.
- Below are presented FLUKA simulations of the 252.7 MeV proton beam impacting on the collimator.



Courtesy of Ivan Strasik & Mauro Pivi

Medical Physics Project


MOTIVATION

SAVING BEAM TIME!

- Experimental **patient-specific quality assurance (PSQA)**

To verify dose calculation in clinical treatment planning system (**TPS**)

- **Non-human** standardized geometry and material
- Limited **sensitivity** to errors in planned/delivered dose
- **Time consuming**



Independent system to
recalculate dose in
patient geometry


24 PinPoint ICs fixed to the PTW 3D detector block holder
in a PTW MP3-P water phantom

Courtesy of Andreas F. Resch & Yihan Jia

Medical Physics Project

IDEAL

- **Independent DosE cAlculation system for Light ion beam therapy**
- Wrapper for GATE-RTion v1.0/Geant4.10.3.p3
 - GATE-RTion: well validated release of GATE for clinical usage, release cycle \sim 5 years
- Designed for **daily clinical usage**
 \rightarrow automatic workflow
- Integration of IDEAL into **myQA iON**
 - Collaboration with IBA Dosimetry
- First step
 - Absorbed dose validation
- Next step
 - RBE weighted dose validation



Grevillot et al. 2021

THANK YOU FOR YOUR INTEREST!

